Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021090046 - HUMANIZED ANTI-CA IX ANTIBODIES AND METHODS OF THEIR USE

Publication Number WO/2021/090046
Publication Date 14.05.2021
International Application No. PCT/IB2019/059492
International Filing Date 05.11.2019
IPC
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/40 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
C07K 16/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
CPC
C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 16/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
40against enzymes
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/567
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
567Framework region [FR]
C07K 2317/732
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
732Antibody-dependent cellular cytotoxicity [ADCC]
C07K 2317/734
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
734Complement-dependent cytotoxicity [CDC]
Applicants
  • MABPRO A.S. [SK]/[SK]
Inventors
  • ZATOVICOVA, Miriam
  • PASTOREKOVA, Silvia
  • TAKACOVA, Martina
  • BARATHOVA, Monika
  • PASTOREK, Jaromir
Agents
  • HARTVICHOVA, Katerina
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HUMANIZED ANTI-CA IX ANTIBODIES AND METHODS OF THEIR USE
(FR) ANTICORPS ANTI-CA IX HUMANISÉS ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
The present invention relates to a humanized antibody specifically recognizing human CA IX, and to therapeutic and diagnostic methods utilizing this antibody. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.
(FR)
La présente invention concerne un anticorps humanisé qui reconnait de manière spécifique CA IX humain, et des méthodes thérapeutiques et diagnostiques utilisant cet anticorps. Les méthodes concernent en particulier le traitement ou le diagnostic de cancers choisis parmi le carcinome à cellules squameuses, le myélome, le cancer du poumon à petites cellules, le cancer du poumon non à petites cellules, le gliome, le lymphome de Hodgkin, le lymphome non hodgkinien, la leucémie myéloïde aiguë, le myélome multiple, le cancer du tractus gastro-intestinal, le cancer rénale, le cancer de l'ovaire, le cancer du foie, la leucémie lymphoblastique, la leucémie lymphocytaire, le cancer colorectal, le cancer de l'endomètre, le cancer du rein, le cancer de la prostate, le cancer de la thyroïde, le mélanome, le chrondrosarcome, le neuroblastome, le cancer du pancréas, le glioblastome multiforme, le cancer du col de l'utérus, le cancer du cerveau, le cancer de l'estomac, le cancer de la vessie, l'hépatome, le cancer du sein, le carcinome du côlon, le mésothéliome et le cancer de la tête et du cou.
Latest bibliographic data on file with the International Bureau